research
A Cancer Drug Targets the Mitochondrial Shield
A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.
Summary
A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.
University of Vermont researchers and RS Oncology report early clinical testing of a drug that targets PRDX3, a mitochondrial antioxidant protein used by cancer cells to manage oxidative stress. In a phase-one trial involving people with relapsed mesothelioma, the release says 67 percent had disease controlled and some tumors shrank, with tolerability sufficient to continue development. Phase-one studies are small and designed primarily for safety; the findings justify further trials but do not establish superiority over standard treatment.
Why it matters
A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.
Limits and context
- Phase-one studies are small and designed primarily for safety; the findings justify further trials but do not establish superiority over standard treatment.
Key claims
A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.
Qualification: Phase-one studies are small and designed primarily for safety; the findings justify further trials but do not establish superiority over standard treatment.
Evidence: source-2026-07-14-012
Sources
- University of Vermont via EurekAlert: Mesothelioma phase-one trialUniversity of Vermont via EurekAlert · official announcement
Corrections
No corrections have been recorded for this story.